Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature

Nivolumab is a programmed cell death receptor (PD-1) inhibitor that is increasingly used for various malignancies, both as a first line agent and as salvage therapy. Being a PD-1/PD-1 ligand checkpoint inhibitor, it is known to cause autoimmune inflammation of various organs and has been associated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMJ Case Rep
Hauptverfasser: Abdullah, Hafez Mohammad Ammar, Elnair, Radowan, Khan, Uzma Ikhtiar, Omar, Muhammad, Morey-Vargas, Oscar L
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2019
Schlagworte:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6721076/
https://ncbi.nlm.nih.gov/pubmed/31451458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-229568
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge